NCT07215910
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07215910
Title Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Alliance for Clinical Trials in Oncology
Indications
Therapies
Age Groups: adult | senior | child
Covered Countries USA